A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome

Trial Profile

A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2016

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Restless legs syndrome
  • Focus Pharmacokinetics
  • Sponsors Arbor Pharmaceuticals; XenoPort
  • Most Recent Events

    • 15 Jan 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 15 Jan 2016 Planned primary completion date changed from 1 Jan 2017 to 1 May 2016, as reported by ClinicalTrials.gov.
    • 15 Jan 2016 According to a ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top